@article {Rocco2003725作者= {. Rocco和佩德罗·l·席尔瓦和费尔南达帕特里夏·f·克鲁兹和马可·安东尼奥·c·Melo-Junior保罗F.G.M.M. Tierno马科斯·a·莫拉和陆{\ \我}年代Frederico g . De Oliveira Ezequiel a和c c·利马和多斯桑托斯和沃尔特·f·初级和安娜坐落g . Franchini克雷贝尔葆拉·克里费尔南德斯和埃里克Magri奈良f·德·莫拉埃斯和乔斯{\ ' M e}{\ '}力拓j . Gon {\ c c}阿尔维斯和梅勒妮n . Carbonieri Ivonise多斯桑托斯和Nat {\ '} lia f . Paes和Paula V.M.马舍尔Raissa p .罗查和亚历克斯·f·德·卡瓦略和佩德罗·奥古斯托·阿尔维斯和乔斯{\ ' e}路易斯证实{\ c c} a {\ ' o} dena和阿图尔·t·Cordeiro及Daniela B.B. Trivella和拉斐尔·e·马科斯和Ronir r·路易斯和保罗·佩洛西和Jose Roberto拉e Silva},编辑= {},title ={早期使用nitazoxanide温和COVID-19疾病:随机、安慰剂对照试验},体积= {58}= {1},elocation-id = {2003725} = {2021}, doi ={10.1183/13993003.03725 -2020},出版商={欧洲呼吸学会},抽象={背景nitazoxanide广泛使用和产生广谱抗病毒活性体外。188bet官网地址然而,目前没有证据表明它对严重急性呼吸系统综合症冠状病毒的影响2 (SARS-CoV-2)感染。方法在一个多中心、随机、双盲、安慰剂对照试验,成人患者冠状病毒病发作后3天2019 (COVID-19)症状(干咳嗽、发烧和/或疲劳)登记。确认后SARS-CoV-2感染鼻咽拭子使用逆转录酶聚合酶链反应,患者随机1:1,nitazoxanide接受(500毫克)或安慰剂,每天三次,5天。主要结果是症状完全消失。次要结果病毒载量、实验室测试、血清炎症生物标记和住院率。不良事件也被评估。结果从6月8日到8月20日,2020年,1575名患者筛选。其中,392(198安慰剂,194 nitazoxanide)进行分析。中位数(四分位范围)从出现症状到首次剂量的研究药物5 (4 {\ textendash} 5)天。 At the 5-day study visit, symptom resolution did not differ between the nitazoxanide and placebo arms. Swabs collected were negative for SARS-CoV-2 in 29.9\% of patients in the nitazoxanide arm versus 18.2\% in the placebo arm (p=0.009). Viral load was reduced after nitazoxanide compared to placebo (p=0.006). The percentage viral load reduction from onset to end of therapy was higher with nitazoxanide (55\%) than placebo (45\%) (p=0.013). Other secondary outcomes were not significantly different. No serious adverse events were observed.Conclusions In patients with mild COVID-19, symptom resolution did not differ between nitazoxanide and placebo groups after 5 days of therapy. However, early nitazoxanide therapy was safe and reduced viral load significantly.This was the first study to evaluate the effect of early nitazoxanide therapy in mild COVID-19. Nitazoxanide did not accelerate symptom resolution after 5 days of therapy, but did reduce viral load significantly with no serious adverse events. https://bit.ly/37i75pr}, issn = {0903-1936}, URL = {//www.qdcxjkg.com/content/58/1/2003725}, eprint = {//www.qdcxjkg.com/content/58/1/2003725.full.pdf}, journal = {European Respiratory Journal} }